Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tavaborole
Drug ID BADD_D02119
Description Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* infection. Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).
Indications and Usage Indicated for the treatment of onychomycosis (a fungal infection) of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Marketing Status Prescription
ATC Code D01AE24
DrugBank ID DB09041
KEGG ID D10169
MeSH ID C512998
PubChem ID 11499245
TTD Drug ID D05VGL
NDC Product Code 10337-905; 69766-037; 69575-4018; 69097-686; 51672-1397; 58175-0614; 69238-1657; 66039-932; 50909-1702; 62332-467; 71589-010; 0574-0157; 69037-0034; 51862-690; 63629-8704; 68180-958
Synonyms tavaborole | 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole | AN 2690 | AN2690 | AN-2690 | Kerydin
Chemical Information
Molecular Formula C7H6BFO2
CAS Registry Number 174671-46-6
SMILES B1(C2=C(CO1)C=C(C=C2)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Application site dermatitis23.03.04.014; 12.07.01.018; 08.02.01.018--Not Available
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.001--Not Available
Application site rash08.02.01.016; 23.03.13.008; 12.07.01.016--Not Available
Ingrowing nail23.02.05.011--Not Available
Paronychia23.09.04.001; 11.01.12.001--
Skin irritation23.03.04.009--Not Available
Application site exfoliation12.07.01.022; 08.02.01.022; 23.03.07.007--Not Available
The 1th Page    1    Total 1 Pages